



93/1637  
STW  
PATENT

ATTORNEY DOCKET NO. 50154/003001

Certificate of Mailing: Date of Deposit: November 10, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Guy Beardsley

Printed name of person mailing correspondence

Guy Beardsley

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jeffrey A. Hubbell et al. Art Unit: 1637

Serial No.: 09/586,937 Examiner: J. Riley

Filed: June 2, 2000 Customer No.: 21559

Title: CONJUGATE ADDITION REACTIONS FOR THE  
CONTROLLED DELIVERY OF PHARMACEUTICALLY  
ACTIVE COMPOUNDS

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed after the mailing of a Notice of Allowance, but before

payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. A check for \$180.00 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 19, 2004

  
Kristina Bieker-Brady, Ph.D., P.C.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

J. Cooper McDonald, Ph.D.  
Patent Agent  
Reg. No. 52,011

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50154/003001
	Serial No.	09/586,937
	Applicant	Hubbell et al.
	Filing Date	June 2, 2000
	Group	1637
	IDS Filed	November 10, 2004

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5702717	12/30/1997	Han et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 00/44808	08/03/2000	WIPO			
	WO 01/02017	01/11/2001	WIPO			
	WO 98/32466	07/30/1998	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Greenwald et al "Camptothecin-20-PEG Ester Transport Forms: the Effect of Spacer Groups on Antitumor Activity" Bioorganic & Medicinal Chemistry 1998, 6:551-562.					
	Kopecek et al. "Controlled Release of Drug Model from N-(2-Hydroxypropyl)-methacrylamide Copolymers" Ann. N.Y. Acad. Sci. 1985, 446:93-104.					
	Pendri et al. "Antitumor Activity of Paclitaxel-2'-glycinate Conjugated to Poly(ethylene glycol): a Water-soluble Prodrug" Anti-cancer Drug Design 1998, 13:387-395.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	